Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Aligos Therapeutics Inc (ALGS)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$5.02+5.68%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for ALGS yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain sufficient cash to fund operations into late 2026 | Management aims to maintain cash to fund operations into late 2026. | Intact | cash burn accelerates and funding runs out before late 2026 | Cash from operations: $-24.95M FY2026-Q2; GAAP. Published target: cash and investments sufficient to fund operations through Q4 2026. Annual target cannot be compared with a quarterly or TTM observation. Aug 6, 2026-24,950,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative clinical-stage healthcare business, not a profitable compounder today. The long-term thesis remains intact, with management advancing its lead program, but the evidence is mixed and the risk level is high.
The valuation model places ALGS at a 16% premium to peers, and the expectations gap is negative, meaning expectations appear demanding relative to the evidence. The priced-in signal is tagged as justified, with no fragility gates triggered, but confidence in that assessment is medium.
Near term, recent results have been neutral overall, despite earnings beats in May and August and higher reported revenue in the second quarter, including licensing and milestone payments. Management is on track with clinical development, but cash and investments fell to $30.4 million by the end of the second quarter, excluding a later $25 million upfront payment; funding is stated to extend into late 2026. The next results carry meaningful execution risk, and a guidance cut would be a negative signal.
The multi-year view depends on progress in the Phase 2 B-SUPREME study, which enrolled 245 participants, with topline data expected in late Q3 2027. Near term, the key swing factors are guidance, cash use, and whether weakening jobs data raises recession concerns for cyclical healthcare names. Continued strength from healthcare bellwethers could support sector momentum, though that is not specific proof of ALGS's business progress.
Over the next 1 to 3 years, ALGS remains a high-risk clinical-development story with an intact thesis, but ongoing losses and cash needs make execution central. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 2 of 2 supplied quarters. Management reported: ““We strengthened our financial position through non-dilutive capital, including the $25M upfront payment related to the exclusive Greater China license for pevifoscorvir sodium.” “Our cash and cash equivalents are expected to provide sufficient funding of planned operations through the fourth quarter of 2026.”
Advance clinical development of pevifoscorvir sodium | These show progress in clinical and commercial development despite losses. | Improving | clinical development progress stalls or regresses in 2026 | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “The Phase 2 B-SUPREME study (NCT06963710) has completed enrollment with 131 participants enrolled in the HBeAg+ cohort (Part 1a) and 114 participants enrolled in the HBeAg- cohort (Part 2a).” “Topline data for both the HBeAg+ and HBeAg- cohorts are expected in late Q3 2027.” Delivery assessment Nov 4, 2026 |
Increase revenue through clinical and commercial progress | These show progress in clinical and commercial development despite losses. | Intact | YoY revenue growth falls below 4% next year | Revenue: $27.778M FY2026-Q2; GAAP. Published target: sustain revenue growth above 4% annually. Reported actuals cannot certify a consensus target without an explicit period and accounting-basis binding. Aug 6, 202627,778,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-3.99 → $-5.37 · observed estimates
$0.01B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-3.99 | $5,000,000 | 6 / 6 |
| 2026-07-25 | $-3.99 | $5,000,000 | 6 / 6 |
| 2026-07-26 | $-3.99 | $5,000,000 | 6 / 6 |
| 2026-07-27 | $-3.99 | $5,000,000 | 6 / 6 |
| 2026-07-28 | $-3.99 | $5,000,000 | 6 / 6 |
| 2026-07-29 | $-3.99 | $5,000,000 | 6 / 6 |
| 2026-07-30 | $-3.99 | $5,000,000 | 6 / 6 |
| 2026-07-31 | $-3.99 | $5,000,000 | 6 / 6 |
| 2026-08-01 | $-3.99 | $5,000,000 | 6 / 6 |
| 2026-08-02 | $-3.99 | $5,000,000 | 6 / 6 |
| 2026-08-03 | $-3.99 | $5,000,000 | 6 / 6 |
| 2026-08-04 | $-3.99 | $5,000,000 | 6 / 6 |
| 2026-08-05 | $-3.99 | $5,000,000 | 6 / 6 |
| 2026-08-06 | $-3.99 | $5,000,000 | 6 / 6 |
| 2026-08-07 | $-4.48 | $4,285,714 | 5 / 4 |
| 2026-08-08 | $-3.99 | $5,000,000 | 6 / 6 |
| 2026-08-09 | $-3.99 | $5,000,000 | 6 / 6 |
| 2026-08-10 | $-3.99 | $5,000,000 | 6 / 6 |
| 2026-08-11 | $-4.98 | $8,137,500 | 6 / 4 |
| 2026-08-12 | $-5.05 | $5,425,000 | 6 / 6 |
| 2026-08-13 | $-5.05 | $5,425,000 | 6 / 6 |
| 2026-08-14 | $-4.48 | $4,285,714 | 5 / 4 |
| 2026-08-15 | $-4.48 | $4,285,714 | 5 / 4 |
| 2026-08-16 | $-4.48 | $4,285,714 | 5 / 4 |
| 2026-08-17 | $-4.48 | $4,285,714 | 5 / 4 |
| 2026-08-18 | $-4.48 | $4,285,714 | 5 / 4 |
| 2026-08-19 | $-4.48 | $4,285,714 | 5 / 4 |
| 2026-08-20 | $-5.18 | $4,068,749 | 5 / 4 |
| 2026-08-21 | $-5.18 | $4,068,749 | 5 / 4 |
| 2026-08-22 | $-5.18 | $4,068,749 | 5 / 4 |
| 2026-08-23 | $-5.18 | $4,068,749 | 5 / 4 |
| 2026-08-24 | $-5.18 | $4,068,749 | 5 / 4 |
| 2026-08-25 | $-5.18 | $4,068,749 | 5 / 4 |
| 2026-08-26 | $-5.18 | $4,068,749 | 5 / 4 |
| 2026-08-27 | $-5.18 | $4,068,749 | 5 / 4 |
| 2026-08-28 | $-5.18 | $4,068,749 | 5 / 4 |
| 2026-08-29 | $-5.18 | $4,068,749 | 5 / 4 |
| 2026-08-30 | $-5.18 | $4,068,749 | 5 / 4 |
| 2026-08-31 | $-5.18 | $4,068,749 | 5 / 4 |
| 2026-09-01 | $-5.18 | $4,068,749 | 5 / 4 |
| 2026-09-02 | $-5.18 | $4,068,749 | 5 / 4 |
| 2026-09-03 | $-5.18 | $4,068,749 | 5 / 4 |
| 2026-09-04 | $-5.18 | $4,068,749 | 5 / 4 |
| 2026-09-05 | $-5.18 | $4,068,749 | 5 / 4 |
| 2026-09-06 | $-5.18 | $4,068,749 | 5 / 4 |
| 2026-09-07 | $-5.18 | $4,068,749 | 5 / 4 |
| 2026-09-08 | $-5.18 | $4,068,749 | 5 / 4 |
| 2026-09-09 | $-5.18 | $4,068,749 | 5 / 4 |
| 2026-09-10 | $-5.18 | $4,068,749 | 5 / 4 |
| 2026-09-11 | $-5.18 | $4,068,749 | 5 / 4 |
| 2026-09-12 | $-5.18 | $4,068,749 | 5 / 4 |
| 2026-09-13 | $-5.18 | $4,068,749 | 5 / 4 |
| 2026-09-14 | $-5.18 | $4,068,749 | 5 / 4 |
| 2026-09-15 | $-5.18 | $4,068,749 | 5 / 4 |
| 2026-09-16 | $-5.18 | $4,068,749 | 6 / 5 |
| 2026-09-17 | $-5.18 | $4,068,749 | 6 / 5 |
| 2026-09-18 | $-5.18 | $4,068,749 | 6 / 5 |
| 2026-09-19 | $-5.18 | $4,068,749 | 6 / 5 |
| 2026-09-20 | $-5.18 | $4,068,749 | 6 / 5 |
| 2026-09-21 | $-5.18 | $4,068,749 | 6 / 5 |
| 2026-09-22 | $-5.18 | $4,068,749 | 6 / 5 |
| 2026-09-23 | $-5.18 | $4,068,749 | 6 / 5 |
| 2026-09-24 | $-5.18 | $4,068,749 | 6 / 5 |
| 2026-09-25 | $-5.18 | $4,068,749 | 6 / 5 |
| 2026-09-26 | $-5.18 | $4,068,749 | 6 / 5 |
| 2026-09-27 | $-5.18 | $4,068,749 | 6 / 5 |
| 2026-09-28 | $-5.18 | $4,068,749 | 6 / 5 |
| 2026-09-29 | $-5.18 | $4,068,749 | 6 / 5 |
| 2026-09-30 | $-5.18 | $4,068,749 | 6 / 5 |
| 2026-10-01 | $-5.18 | $4,068,749 | 6 / 5 |
| 2026-10-02 | $-5.18 | $4,068,749 | 6 / 5 |
| 2026-10-03 | $-5.18 | $4,068,749 | 6 / 5 |
| 2026-10-04 | $-5.18 | $4,068,749 | 6 / 5 |
| 2026-10-05 | $-5.18 | $4,068,749 | 6 / 5 |
| 2026-10-06 | $-5.18 | $4,068,749 | 6 / 5 |
| 2026-10-07 | $-5.18 | $4,068,749 | 6 / 5 |
| 2026-10-08 | $-5.18 | $4,068,749 | 6 / 5 |
| 2026-10-09 | $-5.18 | $4,068,749 | 6 / 5 |
| 2026-10-10 | $-5.18 | $4,068,749 | 6 / 5 |
| 2026-10-11 | $-5.18 | $4,068,749 | 6 / 5 |
| 2026-10-12 | $-5.18 | $4,068,749 | 6 / 5 |
| 2026-10-13 | $-5.18 | $4,068,749 | 6 / 5 |
| 2026-10-14 | $-5.18 | $4,068,749 | 6 / 5 |
| 2026-10-15 | $-5.18 | $4,068,749 | 6 / 5 |
| 2026-10-16 | $-5.18 | $4,068,749 | 6 / 5 |
| 2026-10-17 | $-5.18 | $4,068,749 | 6 / 5 |
| 2026-10-18 | $-5.18 | $4,068,749 | 6 / 5 |
| 2026-10-19 | $-5.18 | $4,068,749 | 6 / 5 |
| 2026-10-20 | $-5.18 | $4,068,749 | 6 / 5 |
| 2026-10-21 | $-5.18 | $4,068,749 | 6 / 5 |
| 2026-10-22 | $-5.18 | $4,068,749 | 6 / 5 |
| 2026-10-23 | $-5.18 | $4,068,749 | 6 / 5 |
| 2026-10-24 | $-5.37 | $4,068,749 | 6 / 5 |
| 2026-10-25 | $-5.37 | $4,068,749 | 6 / 5 |
| 2026-10-26 | $-5.37 | $4,068,749 | 6 / 5 |
| 2026-10-27 | $-5.37 | $4,068,749 | 6 / 5 |
| 2026-10-28 | $-5.37 | $4,068,749 | 6 / 5 |
| 2026-10-29 | $-5.37 | $4,068,749 | 6 / 5 |
| 2026-10-30 | $-5.37 | $4,068,749 | 6 / 5 |
| 2026-10-31 | $-5.37 | $4,068,749 | 6 / 5 |
| 2026-11-01 | $-5.37 | $4,068,749 | 6 / 5 |
| 2026-11-02 | $-5.37 | $4,068,749 | 6 / 5 |
| 2026-11-03 | $-5.37 | $4,068,749 | 6 / 5 |
| 2026-11-04 | $-5.37 | $4,068,749 | 6 / 5 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 8 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.